跳转至内容
Merck
CN

G6793

GW7647

≥98% (HPLC), Potent human PPARα agonist

别名:

2-(4-(2-(1-环己烷丁基)-3-环己基脲基)乙基)苯硫基)-2-甲基丙酸

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C29H46N2O3S
化学文摘社编号:
分子量:
502.75
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

GW7647, ≥98% (HPLC)

SMILES string

CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3)cc1)C(O)=O

InChI key

PKNYXWMTHFMHKD-UHFFFAOYSA-N

InChI

1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)

assay

≥98% (HPLC)

color

white

solubility

DMSO: soluble 16 mg/mL
H2O: insoluble

Quality Level

Gene Information

human ... PPARA(5465)

Application

GW7647已被用作过氧化物酶体增殖物激活受体α (PPAR α)配体:
  • 脱脂培养基,用于治疗原代人肝细胞
  • 测试对心肌细胞糖酵解功能的影响
  • 测试对幼鼠心脏的影响
  • 在乳腺癌MDA-MB-231细胞中激活PPAR

Biochem/physiol Actions

GW7647可降低血清甘油三酯水平,提高β-氧化相关基因的肝脏表达。GW7647与二甲双胍联合应用可提高肝脏脂肪变性或损伤情况下血清中天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)的水平。
强效人PPARα激动剂。用于研究人细胞中PPARα受体的生物学。

Features and Benefits

该化合物在受体分类和信号转导手册的 核受体(PPAR) 页面上有详细描述。如需浏览其他手册页面,请点击此处

Legal Information

根据Glaxo­Smith­Kline协议,仅为研究目的出售

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jun Zhang et al.
Oncotarget, 8(13), 20766-20783 (2017-02-12)
Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus therapy. The severe effects of known glitazones and the successfully approved agents (saroglitazar and lobeglitazone) motivated us to study novelly potent PPARs drugs with
Anne Mazzucotelli et al.
Diabetes, 56(10), 2467-2475 (2007-07-25)
The purpose of this work was to determine the pattern of genes regulated by peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1 alpha) in human adipocytes and the involvement of PPARalpha and PPARgamma in PGC-1 alpha transcriptional action. Primary
Yanjie Cheng et al.
Molecular therapy. Nucleic acids, 9, 195-206 (2017-12-17)
Widely varied compounds, including certain plasticizers, hypolipidemic drugs (e.g., ciprofibrate, fenofibrate, WY-14643, and clofibrate), agrochemicals, and environmental pollutants, are peroxisome proliferators (PPs). Appropriate dose of PPs causes a moderate increase in the number and size of peroxisomes and the expression
Sriram Ramanan et al.
Free radical biology & medicine, 45(12), 1695-1704 (2008-10-15)
Whole-brain irradiation (WBI) can lead to cognitive impairment several months to years after irradiation. Studies on rodents have shown a rapid and sustained increase in activated microglia (brain macrophages) following brain irradiation, contributing to a chronic inflammatory response and a
Luisa Vergori et al.
Stem cells translational medicine, 7(1), 135-145 (2017-10-29)
Metabolic pathologies such as diabetes and obesity are associated with decreased level of circulating and bone marrow (BM)-derived endothelial progenitor cells (EPCs). It is known that activation of peroxisome proliferator-activated receptor alpha (PPARα) may stimulate cell differentiation. In addition, microparticles

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持